Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - Tandem Diabetes Care, Inc. reported a quarterly loss of $0.67 per share, which was worse than the Zacks Consensus Estimate of a loss of$ 0.60, and compared to a loss of $0.63 per share a year ago, indicating an earnings surprise of -11.67% [1] - The company posted revenues of$ 234.42 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.44%, and showing an increase from year-ago revenues of $191.67 million [2] - Over the last four quarters, Tandem Diabetes Care has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Tandem Diabetes Care shares have declined approximately 53.4% since the beginning of the year, in contrast to the S&P 500's decline of -5.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$ 0.34 on revenues of $247.82 million, and for the current fiscal year, it is -$ 1.17 on revenues of $1 billion [7] Industry Outlook - The Medical - Instruments industry, to which Tandem Diabetes Care belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The performance of Tandem Diabetes Care's stock may be influenced by the overall outlook for the industry [8]